Skip to main content
SpringerLink
Log in

The Impact of Cryptococcus gattii with a Focus on the Outbreak in North America

  • Chapter
  • First Online:
Dynamic Models of Infectious Diseases

  • 1108 Accesses

Abstract

Cryptococcus gattii is an emerging infectious disease with an expanding geographic range that gained increased attention during the Vancouver Island outbreak in 1999 [54]. Cases of infection with C. gattii were first reported in regions of Africa and Australia [46, 57]. C. gattii has been environmentally isolated from eucalyptus and other trees from tropical and subtropical regions [63, 123]. Prior to the 1999 outbreak, C. gattii infections were extremely rare in temperate regions of North America [12, 87]. Subsequently, C. gattii has been recognized as a cause of outbreak infections in Vancouver Island, British Columbia, and the Pacific Northwest United States. It also has been seen as a cause of low-level sporadic infections in other parts of North America and worldwide. Interestingly, the genotypes of the outbreak C. gattii strains differ from the genotypes of the C. gattii strains causing sporadic infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alvarado-Ramirez E, Torres-Rodriguez JM, Sellart M, Vidotto V (2008) Laccase activity in Cryptococcus gattii strains isolated from goats. Rev Iberoam Micol 25:150–153

    PubMed  Google Scholar 

  2. Alvarez M, Casadevall A (2006) Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol 16(21):2161–2165

    PubMed  CAS  Google Scholar 

  3. Alvarez M, Saylor C, Casadevall A (2008) Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation. Cell Microbiol 10:1622–1633

    PubMed  CAS  Google Scholar 

  4. Bacon BE, Cherniak R, Kwon-Chung KJ, Jacobson ES (1996) Structure of the 0-deacteylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy. Carbohydr Res 283:95–110

    PubMed  CAS  Google Scholar 

  5. Banerjee U, Gupta K, Venugopal P (1997) A case of prosthetic valve endocarditis caused by Cryptococcus neoformans var. neoformans. J Med Vet Mycol 35:139–141

    PubMed  CAS  Google Scholar 

  6. Bartlett KH, Kidd SE, Kronstad JW (2007) The emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. Curr Fungal Infect Rep 10(1):108–115

    Google Scholar 

  7. Boekhout T, Theelen B, Diaz M, Fell JW, Hop WCJ, Abeln ECA, Dromer F, Meyer W (2001) Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 147:891–907

    PubMed  CAS  Google Scholar 

  8. Boekhout T, van Belkum A, Leenders AC, Verbrugh HA, Mukamurangwa P, Swinne D, Scheffers WA (1997) Molecular typing of Cryptococcus neoformans: taxonomic and epidemiological aspects. Int J Syst Bacteriol 47(2):432–442

    PubMed  CAS  Google Scholar 

  9. Bolanos B, Mitchell TG (1989) Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages. J Med Vet Mycol 27:203–217

    PubMed  CAS  Google Scholar 

  10. Bovers M, Hagen F, Kuramae EE, Boekhout T (2008) Six monophyletic lineages identified within Cryptococcus neoformans and Cryptococcus gattii by multilocus sequence typing. Fungal Genet Biol 45:400–421

    PubMed  CAS  Google Scholar 

  11. Bovers M, Hagen F, Boekhout T (2008) Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol 25(1):S4–S12

    PubMed  Google Scholar 

  12. Brandt ME, Hutwagner LC, Klug LA, Baughman WS, Rimland D, Cryptococcal Disease Active Surveillance Group et al (1996) Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J Clin Microbiol 34(4):912–917

    PubMed  CAS  Google Scholar 

  13. Braun DK, Janssen DA, Marcus JR, Kauffman CA (1994) Cryptococcal infection of a prosthetic dialysis fistula. Am J Kidney Dis 24:864–867

    PubMed  CAS  Google Scholar 

  14. Brouwer AE, Teparrukkul P, Pinpraphaporn S, Larsen RA, Chierakul W, Peacock S, Day N, White NJ, Harrison TS (2005) Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis 192:681–684

    PubMed  Google Scholar 

  15. Brueske CH (1986) Proteolytic activity of a clinical isolate of Cryptococcus neoformans. J Clin Microbiol 23(3):631–633

    PubMed  CAS  Google Scholar 

  16. Byrnes EJ, Marr KA (2011) The outbreak of Cryptococcus gattii in western North America: epidemiology and clinical issues. Curr Infect Dis Rep 13(3):256–261

    PubMed  Google Scholar 

  17. Byrnes EJ, Bartlett KH, Perfect JR, Heitman J (2011) Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microb Infect 13:895–907

    CAS  Google Scholar 

  18. Byrnes EJ, Li W, Ren P, Lewit Y, Voelz K, Fraser JA, Dietrich FS, May RC, Chaturvedi S, Chaturvedi V, Heitman J (2011) A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. PLoS Pathog 7(9):e1002205

    PubMed  CAS  Google Scholar 

  19. Byrnes EJ, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chaturvedi V, Bildfell RJ, May RC, Heitman J (2010) Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 6(4):e1000850

    PubMed  Google Scholar 

  20. Byrnes EJ, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, Heitman J (2009) Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis 199:1081–1086

    PubMed  Google Scholar 

  21. Campbell LT, Currie BJ, Krockenberger M, Malik R, Meyer W, Heitman J, Carter D (2005) Clonality and recombination in genetically differentiated subgroups of Cryptococcus gattii. Eukaryot Cell 4(8):1403–1409

    PubMed  CAS  Google Scholar 

  22. Campbell LT, Fraser JA, Nichols CB, Dietrich FS, Carter D, Heitman J (2005) Clinical and environmental isolates of Cryptococcus gattii from Australia that retain sexual fecundity. Eukaryot Cell 4:1410–1419

    PubMed  CAS  Google Scholar 

  23. Carriconde F, Gilgado F, Arthur I, Ellis D, Malik R, van de Wiele N, Robert V, Currie BJ, Meyer W (2011) Clonality and α-a recombination in the Australian Cryptococcus gattii VGII population–an emerging outbreak in Australia. PLoS One 6(2):e16936

    PubMed  CAS  Google Scholar 

  24. Casadevall A, Perfect JR (1998) Cryptococcus neoformans. ASM Press, Washington, DC, USA

    Google Scholar 

  25. Centers for Disease Control and Prevention (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR 58(RR-4):1–207

    Google Scholar 

  26. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F (2005) Capsule structure changes associated with Cryptococcus neoformans crossing of the blood–brain barrier. Am J Pathol 166:421–432

    PubMed  CAS  Google Scholar 

  27. Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V (2005) Cryptococcus gattii in AIDS patients, southern California. Emerg Infect Dis 11:1686–1692

    PubMed  CAS  Google Scholar 

  28. Chayakulkeeree M, Perfect JR (2006) Cryptococcosis. Infect Dis Clin North Am 20(3):507–544, v–vi

    PubMed  Google Scholar 

  29. Chen LC, Blank ES, Casadevall A (1996) Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Lab Immunol 3(5):570–574

    PubMed  CAS  Google Scholar 

  30. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, Byth K, Australasian Cryptococcal Study Group (2000) Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 31(2):499–508

    PubMed  CAS  Google Scholar 

  31. Chen SCA, Wright LC, Golding JC, Sorrell TC (2000) Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochem J 347(2):431–439

    PubMed  CAS  Google Scholar 

  32. Chen SCA, Currie BJ, Campbell HM, Fisher DA, Pfeiffer TJ, Ellis DH, Sorrell TC (1997) Cryptococcus neoformans var. gattii infection in northern Australia: existence of an environmental source other than known host eucalypts. Trans R Soc Trop Med Hyg 91:547–550

    PubMed  CAS  Google Scholar 

  33. Cheng PY, Sham A, Kronstad JW (2009) Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neoformans. Infect Immun 77:4284–4294

    PubMed  CAS  Google Scholar 

  34. Cherniak R, Sundstrom JB (1994) Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 62(5):1507–1512

    PubMed  CAS  Google Scholar 

  35. Chong HS, Dagg R, Malik R, Chen S, Carter D (2010) In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol 48(11):4115–4120

    PubMed  Google Scholar 

  36. Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J (2011) In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 60(7):961–967

    PubMed  Google Scholar 

  37. Clemons KV, Calich VL, Burger E, Filler SG, Grazziutti M, Murphy J, Roilides E, Campa A, Dias MR, Edwards JE Jr, Fu Y, Fernandes-Bordignon G, Ibrahim A, Katsifa H, Lamaignere CG, Meloni-Bruneri LH, Rex J, Savary CA, Xidieh C (2000) Pathogenesis I: interactions of host cells and fungi. Med Mycol 38(Suppl 1):99–111

    PubMed  Google Scholar 

  38. D’Souza CA, Kronstad JW, Taylor G, Warren R, Yuen M, Hu G, Jung WH, Sham A, Kidd SE, Tangen K, Lee N, Zeilmaker T, Sawkins J, McVicker G, Shah S, Gnerre S, Griggs A, Zeng Q, Bartlett K, Li W, Wang X, Heitman J, Stajich JE, Fraser JA, Meyer W, Carter D, Schein J, Krzywinski M, Kwon-Chung KJ, Varma A, Wang J, Brunham R, Fyfe M, Ouellette BF, Siddiqui A, Marra M, Jones S, Holt R, Birren BW, Galagan JE, Cuomo CA (2011) Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. mBio 2(1):e00342–10

    PubMed  Google Scholar 

  39. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, Hoang L, Leslie MJ, MacDougall L, Magill SS, Morshed MG, Marr KA et al (2009) Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis 15(8):1185–1191

    PubMed  Google Scholar 

  40. Datta K, Bartlett KH, Marr KA (2009) Cryptococcus gattii: emergence in western north America: exploitation of a novel ecological niche. Interdiscip Perspect Infect Dis 2009:176532

    PubMed  Google Scholar 

  41. DeBess E, Cieslak PR, Marsden-Haug N, Goldoft M, Wohrle R, Free C, Dykstra E, Nett RJ, Chiller T, Lockhart SR, Harris J (2010) Emergence of Cryptococcus gattii—Pacific Northwest, 2004–2010. MMWR Morb Mortal Wkly Rep 59(28):865–868

    Google Scholar 

  42. Diaz MR, Boekhout T, Kiesling T, Fell JW (2005) Comparative analysis of the intergenic spacer regions and population structure of the species complex of the pathogenic yeast Cryptococcus neoformans. FEMS Yes Res 5:129–1140

    Google Scholar 

  43. Diaz MR, Boekhout T, Theelen B, Fell JW (2000) Molecular sequence analyses of the intergenic spacer (IGS) associated with rDNA of the two varieties of the pathogenic yeast, Cryptococcus neoformans. Syst Appl Microbiol 23(4):535–545

    PubMed  CAS  Google Scholar 

  44. Dong ZM, Murphy JW (1995) Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun 63:2632–2644

    PubMed  CAS  Google Scholar 

  45. Ellis DH (1987) Cryptococcus neoformans var. gattii in Australia. J Clin Microbiol 25(2):430–431

    PubMed  CAS  Google Scholar 

  46. Ellis DH, Pfeiffer TJ (1990) Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 28(7):1642–1644

    PubMed  CAS  Google Scholar 

  47. Erickson T, Liu L, Gueyikian A, Zhu X, Gibbons J, Williamson PR (2001) Multiple virulence factors of Cryptococcus neoformans are dependent on VPH1. Mol Microbiol 42:1121–1131

    PubMed  CAS  Google Scholar 

  48. Erke KH (1976) Light microscopy of basidia, basidiospores, and nuclei in spores and hyphae of Filobasidiella neoformans (Cryptococcus neoformans). J Bacteriol 128:445–455

    PubMed  CAS  Google Scholar 

  49. Feldmesser M, Tucker S, Casadevall A (2001) Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol 9(6):273–278

    PubMed  CAS  Google Scholar 

  50. Findley K, Rodriguez-Carres M, Metin B, Kroiss J, Fonseca A, Vilgalys R, Heitman J (2009) Phylogeny and phenotypic characterization of pathogenic cryptococcus species and closely related saprobic taxa in the tremellales. Eukaryt Cell 8:353–361

    CAS  Google Scholar 

  51. Fonseca FL, Nohara LL, Cordero RJ, Frases S, Casadevall A, Almeida IC, Nimrichter L, Rodrigues ML (2010) Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter. Infect Immun 78(9):3861–3870

    PubMed  Google Scholar 

  52. Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, Allen A, Stajich JE, Dietrich FS, Perfect JR, Heitman J (2005) Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437:1360–1364

    PubMed  CAS  Google Scholar 

  53. Fraser JA, Subaran RL, Nichols CB, Heitman J (2003) Recapitulation of the sexual cycle of the primary fungal pathogen Cryptococcus neoformans var. gattii: implications for an outbreak on Vancouver Island, Canada. Eukaryot Cell 2:1036–1045

    PubMed  CAS  Google Scholar 

  54. Fyfe M, MacDougall L, Romney M, Starr M, Pearce M, Mak S, Mithani S, Kibsey P (2008) Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. Can Commun Dis Rep 34(6):1–12

    PubMed  CAS  Google Scholar 

  55. Galanis E, MacDougall L, Kidd S, Morshed M, British Columbia Cryptococcus gattii Working Group (2010) Epidemiology of Cryptococcocus gattii, British Columbia, Canada, 1999–2007. Emerg Infect Dis 16(2):251–257

    PubMed  Google Scholar 

  56. Garcia-Hermoso D, Dromer F, Janbon G (2004) Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun 72:3359–3365

    PubMed  CAS  Google Scholar 

  57. Gatti F, Eeckels R (1970) An atypical strain of Cryptococcus neoformans (San Felice) Vuillemin 1894. I. Description of the disease and of the strain. Ann Soc Belges Med Trop Parasitol Mycol 50:689–693

    PubMed  CAS  Google Scholar 

  58. Giles SS, Batinic-Haberle I, Perfect JR, Cox GM (2005) Cryptococcus neoformans mitochondrial superoxide dismutase: an essential link between antioxidant function and high-temperature growth. Eukaryot Cell 4:46–54

    PubMed  CAS  Google Scholar 

  59. Gillece JD, Schupp JM, Balajee SA, Harris J, Pearson T, Yan Y, Keim P, DeBess E, Marsden-Haug N, Wohrle R, Engelthaler DM, Lockhart SR (2011) Whole genome sequence analysis of Cryptococcus gattii from the Pacific Northwest reveals unexpected diversity. PLoS One 6:e28550

    PubMed  CAS  Google Scholar 

  60. Goulart L, Silva LK, Chiapello L, Silveira C, Crestani J, Masih D, Vainstein MH (2010) Cryptococcus neoformans and Cryptococcus gattii genes preferentially expressed during rat macrophage infection. Med Mycol 48:932–941

    PubMed  CAS  Google Scholar 

  61. Granger DL, Perfect JR, Durack DT (1985) Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest 76:508–516

    PubMed  CAS  Google Scholar 

  62. Gupta G, Fries BC (2010) Variability of phenotypic traits in Cryptococcus varieties and species and the resulting implications for pathogenesis. Future Microbiol 5(5):775–787

    PubMed  Google Scholar 

  63. Hagen F, Boekhout T (2010) The search for the natural habitat of Cryptococcus gattii. Mycopathologia 170:209–211

    PubMed  Google Scholar 

  64. Hagen F, van Assen S, Luijckx GJ, Boekhout T, Kampinga GA (2010) Activated dormant Cryptococcus gattii infection in a Dutch tourist who visited Vancouver Island (Canada): a molecular epidemiological approach. Med Mycol 48(3):528–531

    PubMed  Google Scholar 

  65. Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF (2010) In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 54(12):5139–5145

    PubMed  CAS  Google Scholar 

  66. Harris J, Lockhart S, Chiller T (2012) Cryptococcus gattii: where do we go from here? Med Mycol 50:113–129

    PubMed  Google Scholar 

  67. Harris JR, Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, Wohrle R, Lee S, Smelser C, Park B, Chiller T (2011) Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 53(12):1188–1195

    PubMed  CAS  Google Scholar 

  68. Hoang LM, Maguire JA, Doyle P, Fyfe M, Roscoe DL (2004) Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997–2002): epidemiology, microbiology and histopathology. J Med Microbiol 53(9):935–940

    PubMed  Google Scholar 

  69. Hu G, Steen BR, Lian T, Sham AP, Tam N, Tangen KL, Kronstad JW (2007) Transcriptional regulation by protein kinase A in Cryptococcus neoformans. PLoS Pathog 3(3):e42

    PubMed  Google Scholar 

  70. Iqbal N, DeBess EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, Chiller T, Lockhart SR, Cryptococcus gattii Public Health Working Group (2010) Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 48(2):539–544

    PubMed  CAS  Google Scholar 

  71. Iqbal N, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF (2010) In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 54(12):5139–5145

    Google Scholar 

  72. Ikeda R, Shinoda T, Morita T, Jacobson ES (1993) Characterization of a phenol oxidase from Cryptococcus neoformans var. neoformans. Microbiol Immunol 37:759–764

    PubMed  CAS  Google Scholar 

  73. Ito-Kuwa S, Nakamura K, Aoki S, Vidotto V (2007) Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses 50(4):277–281

    PubMed  CAS  Google Scholar 

  74. Jackson A, Hosseinipour MC (2010) Management of cryptococcal meningitis in sub-saharan Africa. Curr HIV/AIDS Rep 7(3):134–142

    PubMed  Google Scholar 

  75. Jacobson ES, Emery HS (1991) Temperature regulation of the cryptococcal phenoloxidase. J Med Vet Mycol 29:121–124

    PubMed  CAS  Google Scholar 

  76. Jain N, Li L, Hsueh YP, Guerrero A, Heitman J, Goldman DL, Fries BC (2009) Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformans. Infect Immun 7(7):128–140

    Google Scholar 

  77. Jain N, Li L, McFadden DC, Banarjee U, Wang X, Cook E, Fries BC (2006) Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infect Immun 74(2):896–903

    PubMed  CAS  Google Scholar 

  78. Kerkering TM, Duma RJ, Shadomy S (1981) The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 94(5):611–616

    PubMed  CAS  Google Scholar 

  79. Khan ZU, Randhawa HS, Chehadeh W, Chowdhary A, Kowshik T, Chandy R (2009) Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole. Int J Antimicrob Agents 33(6):559–563

    PubMed  CAS  Google Scholar 

  80. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, MacDougall L, Boekhout T, Kwon-Chung KJ, Meyer W (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci 101:17258–17263

    PubMed  CAS  Google Scholar 

  81. Kidd SE, Sorrell TC, Meyer W (2003) Isolation of two molecular types of Cryptococcus neoformans var. gattii from insect frass. Med Mycol 41(2):171–176

    PubMed  CAS  Google Scholar 

  82. Kwon-Chung KJ (1980) Nuclear genotypes of spore chains in Filobasidiella neoformans (Cryptococcus neoformans). Mycologia 72:418–422

    PubMed  CAS  Google Scholar 

  83. Kwon-Chung KJ (1976) Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia 68:821–833

    PubMed  CAS  Google Scholar 

  84. Kwon-Chung KJ, Bennett JE (1984) Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 120(1):123–130

    PubMed  CAS  Google Scholar 

  85. Kwong-Chung KJ, Bennett JE (1978) Distribution of α and α mating types of Cryptococcus neoformans among natural and clinical isolates. Am J Epidemiol 108(4):337–340

    Google Scholar 

  86. Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M (2002) Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51:804–806

    Google Scholar 

  87. Kwon-Chung KJ, Polacheck I, Bennett JE (1982) Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 15:525–537

    Google Scholar 

  88. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM (1994) Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 19(4):741–745

    PubMed  CAS  Google Scholar 

  89. Laurenson IF, Lalloo DG, Naragi S, Seaton RA, Trevett AJ, Matuka A, Kevau IH (1997) Cryptococcus neoformans in Papua New Guinea: a common pathogen but an elusive source. J Med Vet Mycol 35(6):437–440

    PubMed  CAS  Google Scholar 

  90. Lee A, Toffaletti DL, Tenor J, Soderblom EJ, Thompson JW, Moseley MA, Price M, Perfect JR (2010) Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect Immun 78:4213–4225

    PubMed  CAS  Google Scholar 

  91. Lin X, Hull CM, Heitman J (2005) Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature 434(7036):1017–1021

    PubMed  CAS  Google Scholar 

  92. Litvintseva AP, Thakur R, Reller LB, Mitchell TG (2005) Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa. J Infect Dis 192(5):888–892

    PubMed  CAS  Google Scholar 

  93. Littman ML, Tsubura E (1959) Effect of degree of encapsulation upon virulence of Cryptococcus neoformans. Proc Soc Exp Biol Med 101:773–777

    PubMed  CAS  Google Scholar 

  94. Liu L, Tewari RP, Williamson PR (1999) Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages. Infect Immun 67:6034–6039

    PubMed  CAS  Google Scholar 

  95. Lupo P, Chang YC, Kelsall BL, Farber JM, Pietrella D, Vecchiarelli A, Leon F, Kwon-Chung KJ (2008) The presence of capsule in Cryptococcus neoformans influences the gene expression profile in dendritic cells during interaction with the fungus. Infect Immun 76(4):1581–1589

    PubMed  CAS  Google Scholar 

  96. Ma H, Hagen F, Stekel DJ, Johnston SA, Sionov E, Falk R, Polacheck I, Boekhout T, May RC (2009) The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci USA 106(31):12980–12985

    PubMed  CAS  Google Scholar 

  97. MacDougall L, Fyfe M (2006) Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period. J Clin Microbiol 44(5):1581–1582

    Google Scholar 

  98. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E (2011) Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis 17(2):193–199

    PubMed  Google Scholar 

  99. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, Cieslak PR, Kronstad JW, Morshed MG, Bartlett KH (2007) Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 13(1):42–50

    PubMed  Google Scholar 

  100. Mackenzie EA, Klig LS (2008) Computational modeling and in silico analysis of differential regulation of myo-inositol catabolic enzymes in Cryptococcus neoformans. BMC Mol Biol 9:88. doi:10.1186/1471-2199-9-88

    PubMed  Google Scholar 

  101. Mak S, Klinkenberg B, Bartlett K, Fyfe M (2010) Ecological niche modeling of Cryptococcus gattii in British Columbia, Canada. Environ Health Perspect 118(5):653–658

    PubMed  Google Scholar 

  102. Martinez LR, Casadevall A (2006) Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect Immun 74:6118–6123

    PubMed  CAS  Google Scholar 

  103. Martinez LR, Casadevall A (2006) Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 50:1021–1033

    PubMed  CAS  Google Scholar 

  104. Martinez LR, Christaki E, Casadevall A (2006) Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro. J Infect Dis 194:261–266

    PubMed  CAS  Google Scholar 

  105. Meyer W, Trilles L (2010) Genotyping of the Cryptococcus neoformans/C. gattii species complex. Aust Biochemist 41:11–15

    Google Scholar 

  106. Meyer W, Gilfado F, Ngamskulrungroj P, Trilles L, Hagen F, Castaneda E, Boekhout T (2011) Molecular typing of the Cryptococcus neoformans/Cryptococcus gattii species complex. In: Heitman J, Kozel TJ, Kwon-Chung KJ, Perfect JR, Casadevall A (eds) Cryptococcus: from human pathogen to model yeast. ASM Press, Washington, DC, USA

    Google Scholar 

  107. Monari C, Bistoni F, Vecchiarelli A (2006) Glucuronoxylomannan exhibits potent immunosuppressive properties. FEMS Yeast Res 6(4):537–542

    PubMed  CAS  Google Scholar 

  108. Montagna MT, Viviani MA, Pulito A, Aralla C, Tortorano AM, Fiore L, Barbuti S (1997) Cryptococcus neoformans var. gattii in Italy. Note II. Environmental investigation related to an autochthonous clinical case in Apulia. J Mycol Med 7:93–96

    Google Scholar 

  109. Muller HE, Sethi KK (1972) Proteolytic activity of Cryptococcus neoformans against human plasma proteins. Med Microbiol Immunol 158(2):129–134

    PubMed  CAS  Google Scholar 

  110. Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, Schutze N, Straubinger RK, Blessing M, McKenzie AN, Brombacher F, Alber G (2007) IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol 179:5367–5377

    PubMed  Google Scholar 

  111. Narasipura SD, Chaturvedi V, Chaturvedi S (2005) Characterization of Cryptococcus neoformans variety gattii SOD2 reveals distinct roles of the two superoxide dismutases in fungal biology and virulence. Mol Microbiol 55(6):1782–1800

    PubMed  CAS  Google Scholar 

  112. Neilson JB, Fromtling RA, Blumer GS (1981) Pseudohyphal forms of Cryptococcus neoformans: decreased survival in vivo. Mycopathologia 73:57–59

    PubMed  CAS  Google Scholar 

  113. Neilson JB, Ivey MH, Bulmer GS (1978) Cryptococcus neoformans pseudohyphal forms surviving culture with Acanthamoeba polyphaga. Infect Immun 20:262–266

    PubMed  CAS  Google Scholar 

  114. Ngamskulrungroj P, Serena C, Gilgado F, Malik R, Meyer W (2011) Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype. Clin Microbiol Infect 17(2):251–258

    PubMed  CAS  Google Scholar 

  115. Ngamskulrungroj P, Gilgado F, Faganello J, Litvintseva AP, Leal AL, Tsui KM, Mitchell TG, Vainstein MH, Meyer W (2009) Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. PLoS One 4:e5862

    PubMed  Google Scholar 

  116. Ngamskulrungroj P, Himmelreich U, Breger JA, Wilson C, Chayakulkeeree M, Krockenberger MB, Malik R, Daniel HM, Toffaletti D, Djordjevic JT, Mylonakis E, Meyer W, Perfect JR (2009) The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. Infect Immun 77:4584–4596

    PubMed  CAS  Google Scholar 

  117. Ngamskulrungroj P, Serena C, Gilgado F, Malik R, Meyer W (2011) Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype. Clin Microbiol Infect 17(2):251–258

    PubMed  CAS  Google Scholar 

  118. Nosanchuk JD, Casadevall A (1997) Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun 65:1836–1841

    PubMed  CAS  Google Scholar 

  119. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 50(3):338–344

    PubMed  CAS  Google Scholar 

  120. Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB (2004) Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol 164(5):1761–1771

    PubMed  CAS  Google Scholar 

  121. Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI, Anekthananon T, Sungkanuparph S, Supparatpinyo K, Nolen TL, Zimmer LO, Kendrick AS, Johnson P, Sobel JD, Filler SG (2009) A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 48(12):1775–1783

    PubMed  CAS  Google Scholar 

  122. Pfeiffer T, Ellis D (1991) Environmental isolation of Cryptococcus neoformans gattii from California. J Infect Dis 163:929–930

    PubMed  CAS  Google Scholar 

  123. Penk A, Pittrow L (1999) Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants. Mycoses 42:91–96

    PubMed  CAS  Google Scholar 

  124. Perfect JR (2006) Cryptococcus neoformans: a sugar-coated killer. In: Heitman J, Filler S, Edwards J, Mitchell A (eds) Molecular principles of fungal pathogenesis. ASM Press, Washington, DC

    Google Scholar 

  125. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50(3):291–322

    PubMed  Google Scholar 

  126. Pettit RK, Repp KK, Hazen KC (2010) Temperature affects the susceptibility of Cryptococcus neoformans biofilms to antifungal agents. Med Mycol 48(2):421–426

    PubMed  CAS  Google Scholar 

  127. Petzold EW, Himmelreich U, Mylonakis E, Rude T, Toffaletti D, Cox GM, Miller JL, Perfect JR (2006) Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect Immun 74:5877–5887

    PubMed  CAS  Google Scholar 

  128. Pfeiffer TJ, Ellis DH (1992) Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis. J Med Vet Mycol 30:407–408

    PubMed  CAS  Google Scholar 

  129. Pfieffer TJ, Ellis DH (1991) Environmental isolation of Cryptococcus neoformans var. gattii from California. J Infect Dis 163:929–930

    Google Scholar 

  130. Ren P, Springer DJ, Behr MJ, Samsonoff WA, Chaturvedi S, Chaturvedi V (2006) Transcription factor STE12α has distinct roles in morphogenesis, virulence, and ecological fitness of the primary pathogenic yeast Cryptococcus gattii. Eukaryot Cell 5:1065–1080

    PubMed  CAS  Google Scholar 

  131. Rivera J, Feldmesser M, Cammer M, Casadevall A (1998) Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun 66:5027–5030

    PubMed  CAS  Google Scholar 

  132. Ruma-Haynes P, Brownlee AG, Sorrell TC (2000) A rapid method for detecting extracellular proteinase activity in Cryptococcus neoformans and a survey of 63 isolates. J Med Microbiol 49(8):733–737

    PubMed  CAS  Google Scholar 

  133. Rutherford JC, Lin X, Nielsen K, Heitman J (2008) Amt2 permease is required to induce ammonium-responsive invasive growth and mating in Cryptococcus neoformans. Eukaryot Cell 7:237–246

    PubMed  CAS  Google Scholar 

  134. Shen WC, Davidson RC, Cox GM, Heitman J (2002) Pheromones stimulate mating and differentiation via paracrine and autocrine signaling in Cryptococcus neoformans. Eukaryot Cell 1:366–377

    PubMed  CAS  Google Scholar 

  135. Silva DC, Martins MA, Szeszs MW, Bonfietti LX, Matos D, Melhem MS (2012) Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains. Diagn Microbiol Infect Dis 72(4):332–339

    PubMed  CAS  Google Scholar 

  136. Sorell TC (2001) Cryptococcus neoformans variety gattii. Med Mycol 39:155–168

    Google Scholar 

  137. Speed B, Dunt D (1995) Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 21(1):28–34

    PubMed  CAS  Google Scholar 

  138. Springer DJ, Chaturvedi V (2010) Projecting global occurrence of Cryptococcus gattii. Emerg Infect Dis 16(1):14–20

    PubMed  Google Scholar 

  139. Springer DJ, Ren P, Raina R, Dong Y, Behr MJ, McEwen BF, Bowser SS, Samsonoff WA, Chaturvedi S, Chaturvedi V (2010) Extracellular fibrils of pathogenic yeast Cryptococcus gattii are important in ecological niche colonization and mammalian virulence. PLoS One 5:e10978

    PubMed  Google Scholar 

  140. Steele KT, Thakur R, Nthobatsang R, Steenhoff AP, Bisson GP (2010) In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Med Mycol 48(8):1112–1115

    PubMed  Google Scholar 

  141. Steen BR, Zuyderduyn S, Toffaletti DL, Marra M, Jones SJ, Perfect JR, Kronstad J (2003) Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell 2:1336–1349

    PubMed  CAS  Google Scholar 

  142. Stephen C, Lester S, Black W, Fyfe M, Raverty S (2002) Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J 43(10):792–794

    PubMed  Google Scholar 

  143. Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H (2006) In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 49(4):324–330

    PubMed  CAS  Google Scholar 

  144. Thompson GR, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF (2009) Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 53(1):309–311

    PubMed  CAS  Google Scholar 

  145. Torres-Rodríguez JM, Alvarado-Ramírez E, Gutiérrez-Gallego R (2008) Urease activity in Cryptococcus neoformans and Cryptococcus gattii. Rev Iberoam Micol 25(1):27–31

    PubMed  Google Scholar 

  146. Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M (2012) Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol 50(3):328–332

    PubMed  Google Scholar 

  147. Trilles L, Fernández-Torres B, Lazéra Mdos S, Wanke B, Guarro J (2004) In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 42(10):4815–4817

    PubMed  CAS  Google Scholar 

  148. Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, Marr KA (2007) First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J Clin Microbiol 45(9):3086–3088

    PubMed  CAS  Google Scholar 

  149. Voelz K, Lammas DA, May RC (2009) Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun 77(8):3450–3457

    PubMed  CAS  Google Scholar 

  150. Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M (1986) Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiological study. Neurosurgery 18:373–375

    PubMed  CAS  Google Scholar 

  151. Walraven CJ, Gerstein W, Hardison SE, Wormley F, Lockhart SR, Harris JR, Fothergill A, Wickes B, Gober-Wilcox J, Massie L, Ku TS, Firacative C, Meyer W, Lee SA (2011) Fatal disseminated Cryptococcus gattii infection in New Mexico. PLoS One 6(12):e28625

    PubMed  CAS  Google Scholar 

  152. Williamson PR (1994) Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase. J Bacteriol 176:656–664

    PubMed  CAS  Google Scholar 

  153. Varma A, Kwon-Chung KJ (2010) Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother 54(6):2303–2311

    PubMed  CAS  Google Scholar 

  154. Vartivarian SE, Anaissie EJ, Cowart RE, Sprigg HA, Tingler MJ, Jacobson ES (1993) Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis 167:186–190

    PubMed  CAS  Google Scholar 

  155. Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR, Heitman J (2009) Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 77:4345–4355

    PubMed  CAS  Google Scholar 

  156. Vecchiarelli A, Pericolini E, Gabrielli E, Chow SK, Bistoni F, Cenci E, Casadevall A (2011) Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy. Immunotherapy 3(8):997–1005

    PubMed  CAS  Google Scholar 

  157. Voelz K, Lammas DA, May RC (2009) Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun 77(8):3450–3457

    PubMed  CAS  Google Scholar 

  158. World Health Organization (WHO) (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. http://whqlibdoc.who.int/publications/2011/9789241502979_eng.pdf. Accessed 11/01/2013

  159. Xu J, Vilgalys R, Mitchell TG (2000) Multiple gene genealogies reveal recent dispersion and hybridization in the human pathogenic fungus Cryptococcus neoformans. Mol Ecol 9:1471–1481

    PubMed  CAS  Google Scholar 

  160. Young BJ, Kozel TR (1993) Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immunol 61(7):2966–2972

    CAS  Google Scholar 

  161. Yue C, Cavallo LM, Alspaugh JA, Wang P, Cox GM, Perfect JR, Heitman J (1999) The STE12α homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. Genetics 153:1601–1615

    PubMed  CAS  Google Scholar 

  162. Zaragoza O, Casadevall A (2004) Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6:10–15

    PubMed  CAS  Google Scholar 

  163. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A (2009) The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 6(8):133–216

    Google Scholar 

  164. Zaragoza O, Telzak A, Bryan RA, Dadachova E, Casadevall A (2006) The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol 59:67–83

    PubMed  CAS  Google Scholar 

  165. Zaragoza O, Fries BC, Casadevall A (2003) Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun 71:6155–6164

    PubMed  CAS  Google Scholar 

  166. Zaragoza O, Taborda CP, Casadevall A (2003) The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol 33:1957–1967

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This manuscript is dedicated to the memory of our beloved colleague and friend, Dr. Gregory Davenport. We would like to thank Dr. Sarah Hardison for helpful suggestions for the manuscript.

Author information

Authors and Affiliations

  1. University of New Mexico Health Science Center, Albuquerque, NM, USA

    Carla J. Walraven, Gregory C. Davenport & Samuel A. Lee M.D., Ph.D.

  2. Division of Infectious Diseases, New Mexico Veterans Healthcare System, 1501 San Pedro SE, Mail Code: 111-J, Albuquerque, NM, 87108, USA

    Maximillian Jahng, Hallie Rane & Samuel A. Lee M.D., Ph.D.

Authors
  1. Carla J. Walraven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maximillian Jahng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory C. Davenport
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hallie Rane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samuel A. Lee M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel A. Lee M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Foundation for Scientific Research and Technological Innovation, Hyderabad, Andhra Pradesh, India

    V. Sree Hari Rao

  2. University of New Mexico School of Medicine, Albuquerque, New Mexico, USA

    Ravi Durvasula

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Walraven, C.J., Jahng, M., Davenport, G.C., Rane, H., Lee, S.A. (2013). The Impact of Cryptococcus gattii with a Focus on the Outbreak in North America. In: Sree Hari Rao, V., Durvasula, R. (eds) Dynamic Models of Infectious Diseases. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9224-5_7

Download citation

Publish with us

Policies and ethics

Search

Navigation